Cyclophosphamide Injection Recall 2026: Lot Matching and Particulate Matter Workflow

Key Takeaways

What To Remember

• The July 24, 2026 FDA-posted announcement covers three specified lots of Cyclophosphamide for Injection, USP because of steel particulate matter.
• Match the full product record: strength and package, NDC, lot, and expiration; the two 1 g lots share one NDC.
• Stop use and dispensing, quarantine affected stock, document the search, notify the responsible pharmacist, and follow the return instructions.
• User level is recall depth, not a Class I, II, or III classification, and FDA posting does not mean the company announcement was FDA-forced.
• Hazardous-drug controls and technician scope still apply; clinical and patient-specific decisions belong with the pharmacist or appropriate clinician.

The Direct Answer: Match the Lot Before You Move the Product

On July 24, 2026, FDA posted Sunny Pharmtech's company announcement for a voluntary nationwide recall of three lots of Cyclophosphamide for Injection, USP to the user level. The stated reason was the presence of particulate matter identified as steel. The product is sold under the Long Grove Pharmaceuticals brand. The announcement said that no adverse events or injuries associated with the particulate-matter issue had been reported as of the notice.

For a pharmacy technician, the practical answer is precise: compare the physical product with the notice, stop use or dispensing when the product is a confirmed match, quarantine the affected inventory, document the finding, and notify the pharmacist or responsible person. Do not treat every cyclophosphamide product as recalled, and do not decide that a bottle is safe because it looks normal. This is a current case study for PTCE preparation, not patient-specific treatment advice or a prediction of an actual exam question.

• Reason: particulate matter identified as steel.
• Recall status: voluntary nationwide recall to the user level.
• FDA and company announcement date: July 24, 2026.
• As of the announcement: no associated adverse events or injuries had been reported.

The Three Lots: Keep the Product Fields Together

The notice identifies two package presentations and three lots. The two 1 g/vial lots share the same NDC, so the lot number is essential. The 2 g/vial presentation has a different NDC. A technician reviewing inventory should keep the strength, package, NDC, lot, and expiration together rather than copying only the ingredient name into a recall log.

The expiration dates are part of the notice's identifying information, but expiration alone is not enough to establish a match. A different lot with the same expiration is not automatically one of the three listed lots. Conversely, a label that is smudged or difficult to read should not be guessed at. Hold the unresolved product according to local procedure and ask the pharmacist, inventory lead, or other designated responsible person to resolve it through the current recall instructions.

• Cyclophosphamide for Injection, USP, 1 g/vial, 50 mL single-dose vial: NDC 81298-8112-1; lot C23019V1; expiration Oct-2026.
• Cyclophosphamide for Injection, USP, 1 g/vial, 50 mL single-dose vial: NDC 81298-8112-1; lot C24015V1; expiration Apr-2027.
• Cyclophosphamide for Injection, USP, 2 g/vial, 100 mL single-dose vial: NDC 81298-8114-1; lot V24010V1; expiration Mar-2027.

A Reliable Product-Matching Workflow

Start with the current FDA-posted notice and the pharmacy's internal recall procedure. Identify every location where the product could be present: active inventory, receiving or staging areas, prepared orders, return bins, satellite stock, and any other location named by policy. Then compare the package in a consistent order: product and strength, dosage form and package, NDC, lot, and expiration. Manufacturer or brand information provides another useful check. A match on the generic name alone is not a completed review.

When a confirmed match is found, immediately keep it out of dispensing and administration workflow. When the identifiers cannot be resolved, do not make an optimistic assumption just to keep work moving. Separate the product in the designated way and escalate the uncertainty. The goal is not to label unrelated stock as recalled; it is to prevent an unidentified or affected product from silently returning to usable inventory while the responsible person verifies the scope.

• Read the notice before relying on memory or a third-party summary.
• Match NDC and lot; use strength, package, brand, and expiration as supporting fields.
• Check all inventory locations required by local policy.
• Hold unclear matches rather than guessing from a blurred label.
• Record the exact product identifiers and quantity found.

Stop, Quarantine, Notify, and Return

The FDA-posted announcement directs pharmacies, hospitals, and other healthcare providers with recalled product to immediately stop use and dispensing, quarantine all affected inventory, and follow the recall notification for arranging return to Cardinal Health. For study purposes, that sequence matters. Quarantine is a controlled status: the product is separated, clearly identified, and prevented from being selected for normal use. It is not an unlabeled bag placed next to active stock, and it is not an informal note that can be lost at the end of a shift.

Document enough information for another trained person to reconstruct what happened. The record may include when the notice was received, the NDC, lot and expiration, quantity and locations checked, quarantine location, inventory-system action, people notified, and the return reference. Use the pharmacy's actual recall log or system. Do not throw the product away, send it back through an ordinary return, or alter the label unless the authorized instructions and pharmacy procedure require that action.

• Stop use and dispensing of confirmed affected product.
• Quarantine the product in the designated controlled area.
• Notify the pharmacist, inventory lead, or responsible person named by policy.
• Reconcile product and document the search and quantity.
• Arrange return through the recall notification, including the stated Cardinal Health process.

Particulate Matter Changes the Safety Conversation

An injectable product with particulate matter is a product-integrity concern, not a visual nuisance that a technician should solve by looking for a cleaner vial. The FDA notice describes the affected material as steel and includes a risk statement about serious events if product containing particulate matter is administered intravenously. The technician's job in this workflow is to prevent use, preserve the product and its identifying information, document what was found, and escalate. It is not to decide whether a particle is clinically harmless or to assess a patient's risk.

The same boundary applies if a technician notices a suspicious injectable before a recall notice is available. Stop the preparation or dispensing process, protect the product from use, and follow the pharmacy's product-quality or incident-reporting procedure. Do not open, filter, transfer, shake, or otherwise manipulate the vial to make it appear usable. Questions about exposure, symptoms, treatment, patient notification, adverse-event reporting, or clinical urgency require the pharmacist or the responsible clinical and safety channel.

Connect the Case to Hazardous-Drug and Scope Questions

Cyclophosphamide is a medication that appears in hazardous-drug handling guidance, so a recall response does not erase the site's existing hazardous-drug controls. Follow the facility's current procedures for restricted access, personal protective equipment, spill response, waste, and handling of contaminated materials. The correct PPE or cleanup method depends on the setting and its approved policy; this article does not invent a universal kit or direct a technician to handle a damaged vial outside training.

The technician can support a recall by locating stock, reading identifiers, counting and documenting inventory, applying the approved quarantine status, and processing an authorized return. The pharmacist or responsible person determines clinical communication, patient-specific recommendations, adverse-event handling, and any action that requires professional judgment. A PTCE question may present several answers that sound active and helpful. Choose the one that controls the product and escalates the decision instead of independently interpreting a hazardous-drug exposure or telling a patient to change treatment.

Do Not Confuse Recall Level, Recall Class, and FDA Posting

The announcement calls this a voluntary nationwide recall to the user level. Recall level describes how far the action extends through the distribution chain. Recall class is a separate FDA risk classification, generally described as Class I, II, or III in FDA recall resources. A notice can tell you the level without assigning a class, and a risk statement does not authorize a reader to calculate the class. This article therefore does not call the cyclophosphamide action Class I, II, or III.

The FDA page also labels the material as a company announcement and explains that FDA posts company announcements as a public service. That is different from saying FDA forced the company to recall the product. For a practice question, use the words that the source actually uses: voluntary, nationwide, user level, particulate matter identified as steel, and three specified lots. Careful wording is not pedantry here; it prevents a workflow record from overstating the official status of the action.

Exam Signals

What This Looks Like on the PTCE

• A recall notice lists two strengths, two NDCs, three lots, and three different expiration dates.
• Two products share an NDC but have different lot numbers, so the lot cannot be skipped.
• The prompt asks for the first action after a product-integrity concern: stop use, quarantine, document, and escalate.
• The choices confuse user-level recall depth with Class I, II, or III classification.
• A technician is asked to decide patient treatment, adverse-event causality, hazardous-drug cleanup, or final disposition independently.

Method

Step-by-Step Approach

1. Read the current FDA announcement and the pharmacy's recall procedure.
2. Search every inventory location required by policy and compare product, strength, package, NDC, lot, and expiration.
3. Stop use and dispensing of confirmed matches; hold unresolved identifiers instead of guessing.
4. Place affected or unresolved product in the designated quarantine area and preserve its label and packaging.
5. Document quantities, locations checked, identifiers, quarantine status, system actions, and required notifications.
6. Notify the pharmacist or responsible person and arrange return to Cardinal Health only through the recall notification and authorized procedure.

Mistakes

Common Traps and Fixes

Mini Practice

PTCE-Style Practice Questions

Official References

Sources To Verify High-Risk Topics

• FDA-Posted Sunny Pharmtech Cyclophosphamide Recall Announcement
• FDA: Understanding Drug Recalls and Recall Classification
• NIOSH: Hazardous Drugs in Healthcare Settings
• PTCB PTCE Content Outline effective January 2026

Editorial Notes

How To Use This Page

This article is written for PTCE study practice and focuses on repeatable exam-prep reasoning, not patient-specific professional advice. AI tools may assist with explanations, but official references and human editorial review define the content boundaries.

For the content process, see the editorial process. For review standards, see the content review policy. For AI boundaries, see AI usage transparency. To report an issue, use contact and corrections.